Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Símbolo de cotizaciónPCRX
Nombre de la empresaPacira Biosciences Inc
Fecha de salida a bolsaFeb 03, 2011
Director ejecutivoMr. Frank D. Lee
Número de empleados790
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 03
Dirección2000 Sierra Point Parkway
CiudadBRISBANE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94005
Teléfono16502428052
Sitio Webhttps://www.pacira.com/
Símbolo de cotizaciónPCRX
Fecha de salida a bolsaFeb 03, 2011
Director ejecutivoMr. Frank D. Lee
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos